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Introduction 
For decades, those seeking insights into alternatives to prohibiting cannabis supply have turned to 
Europe. For nearly 40 years, the Netherlands has tolerated small retail sales, and in February 2017 
the Dutch Parliament narrowly passed a bill to regulate the supply of cannabis to coffee shops (1). 
Spain’s cannabis social clubs (CSCs), which are supposed to produce cannabis for non-profit 
distribution to club members, have proliferated throughout the country despite some of them being 
forced to shut down. Similar CSCs are now appearing in other parts of Europe (Decorte, 2015; 
Belackova et al., 2016; EMCDDA, 2016).  
For the past five years, however, many of those searching for new developments in cannabis 
regulation have turned their attention to the Western Hemisphere. In 2012, voters in the US states 
of Colorado and Washington passed ballot initiatives to remove the prohibition on cannabis and to 
license profit-maximising firms to produce and sell it. In late 2013, Uruguay became the first country 
in the world to legalise cannabis, although its approach is much more restrictive than that being 
adopted in the United States. Since 2016, four more US states have approved commercial models for 
cannabis — including California, the world’s sixth largest economy — and a bill to allow for-profit 
companies to produce cannabis for non-medical purposes has been introduced in Canada. 
Recently, politicians in at least six European countries (in addition to the Netherlands) have 
introduced legislation to reform cannabis supply laws, with many proposing sales through licensed 
outlets (Hughes et al., 2017). While most of these proposals have already been rejected (Hughes et 
al. 2017), conversations about cannabis regulation are expected to become more frequent and more 
detailed in Europe. With this in mind, the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) has requested a brief report to address the following three questions: 
• What new models of cannabis regulation are emerging worldwide and in Europe? (2) 
• What is the evidence about the impact of these reforms? 
• What are the implications for drug policy and practice in Europe?  
 
What new models of cannabis regulation are emerging worldwide and in Europe? 
When thinking about cannabis reforms it is useful to make at least three distinctions: (i) 
use/possession versus supply, (ii) medical versus non-medical purposes and (iii) whether or not the 
reform was based on a de jure change in policy. 
Use/possession versus supply 
With respect to the first distinction, a number of jurisdictions have reduced penalties for using or 
possessing small amounts of cannabis and, in some places, for the cultivation of a few plants at 
home (EMCDDA, 2001; MacCoun and Reuter, 2001a; Pacula et al., 2005; Raschzok, 2015; Eastwood 
et al., 2016). The EMCDDA’s European Legal Database on Drugs documents significant variation in 
cannabis laws across the continent, but most European justice systems prefer alternatives to 
criminal conviction (e.g. fines, cautions, probation) for cases involving use or possession of small 
                                                            
(1) It is unclear whether or not the bill will pass in the upper house (Financial Times, 2017). 
(2) The main focus of this paper is on cannabis policies governing production and sales, not possession and use. 
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quantities of cannabis (Ballotta et al., 2008) (3). While supply for medical and research purposes is 
permitted under international drug conventions, supply for non-medical or non-research purposes is 
explicitly prohibited. 
Medical versus non-medical purposes 
Another distinction is the purpose of consumption. Cannabis has been used for medicinal purposes 
for thousands of years (O’Shaughnessy, 1843; Grinspoon and Bakalar, 1993), but largely fell out of 
favour in Europe and North America in the 20th century as better medicines were invented and 
prohibition restricted access (EMCDDA, 2008). The 1961 Single Convention on Narcotic Drugs allows 
signatories to produce cannabis for medicinal purposes as long as cultivation is controlled by a 
government agency. There is a growing body of research on the therapeutic benefits of whole-plant 
material and extracts (Hill, 2015; Whiting et al., 2015; National Academies of Sciences, Engineering, 
and Medicine, 2017), and the research base is expected to expand as restrictions on cannabis are 
loosened. There is very little scientific research on the non-medical benefits of cannabis (e.g. 
pleasure or stress relief; Caulkins et al., 2016). 
The top panel of Table 1 presents a list of countries in Australasia, Europe and the Western 
Hemisphere where laws have been passed to allow cannabis production for medical purposes. The 
United States is an outlier in that more than half of the country’s population lives in states where 
cannabis is legally available to those with a physician’s recommendation, but medical cannabis 
remains illegal under federal law. Despite prohibition and a lack of federal support, a federal budget 
amendment is currently in effect until December 2017 blocking federal funds from being used to 
prevent states ‘from implementing their own state laws that authorize the use, distribution, 
possession, or cultivation of medical marijuana’ (for more information, see Trumble, 2017). 
Of the other 11 countries that have passed laws to allow the production of medical cannabis, four 
are in Europe. The Dutch programme allows doctors to prescribe five strains of cannabis with varying 
levels of tetrahydrocannabinol (THC) and cannabidiol (CBD) (Office of Medicinal Cannabis, 2016). 
The Dutch Office of Medicinal Cannabis has licensed one producer, who submits the products to the 
government before they are distributed to pharmacies. While the United Kingdom does not make 
plant material available to patients, it does allow a private company to produce cannabis and create 
extracts that are prescribed in the United Kingdom and elsewhere. In 2013, the Czech Republic 
passed a medical law, and domestically produced cannabis for the programme was first delivered to 
the State Agency for Medical Cannabis in 2016 (before then it had been imported). In 2017, 
Germany passed a law to expand access to medical cannabis and to allow domestic production 
(previously, it could only be imported) (The Local, 2017) (4). 
                                                            
(3) The EMCDDA (2016) has also documented that more than one third of countries do not allow prison 
sentences for minor cannabis offences, stating ‘In many of the countries where the law allows imprisonment 
for such cannabis possession, national guidelines advise against it.’    
(4) Following a 2016 decree of the Turkish Food, Agriculture and Livestock Ministry, cannabis production will be 
allowed in 19 provinces for medical and scientific purposes; growers need permission from the government to 
produce. It is unclear who will be allowed to use cannabis for medical purposes in Turkey (Hurriyet Daily News, 
2016; Sims, 2016).  
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Table 1. Jurisdictions that have passed laws to allow cannabis production for non-research 
purposes (excluding allowances for industrial hemp or personal cultivation) 
 
Country National? Year passed Comments 
Medical 
United States No 1996 (a) 28 states and DC passed laws to allow cannabis products to be 
produced and distributed; at least 15 other states allow physicians 
to recommend CBD oils, but do not necessarily provide legal 
protection for in-state production. This all remains illegal under 
federal law. 
Israel Yes Late 1990s A medical programme was developed on the 1995 
recommendation of a subcommittee of the Israeli Parliament Drug 
Committee. Privately held companies that produce cannabis 
operate under a licence from the Department of Health.  
Netherlands Yes 2000 The Office of Medicinal Cannabis was established in 2000 and 
cannabis flowers were first made available in pharmacies in 2003. 
Only five strains are currently allowed to be prescribed and they 
are all produced by one supplier. 
Canada Yes 2001 Currently, all medical cannabis is supposed to be produced by 
federally licensed private companies and delivered by mail. Efforts 
are being made to eliminate the retail medical dispensaries that 
operate in some jurisdictions.  
Chile Yes Late 2000s A licence to grow cannabis that was granted in 2009 was 
withdrawn before production, but the Supreme Court ruled in 
2012 that the withdrawal was unconstitutional. In 2016, Chile is 
expected to harvest medical cannabis from a large, legal 
plantation. 
United 
Kingdom 
Yes 2010 Since the 1990s GW Pharmaceuticals has produced cannabis 
plants in the United Kingdom to create Sativex and other cannabis-
based extracts. In 2010, the United Kingdom approved Sativex to 
be prescribed for spasticity due to multiple sclerosis (as have many 
countries). 
Czech 
Republic 
Yes 2013 Domestically produced cannabis for the medical programme was 
first delivered to the State Agency for Medical Cannabis in early 
2016 (previously, medical cannabis had to be imported). 
Uruguay Yes 2013 Cannabis will be produced by state-licensed companies and 
available in pharmacies for those with a physician’s prescription. 
Jamaica Yes 2015 The regulations have not been implemented, but there are plans 
to allow small- and large-scale production of medical cannabis for 
residents as well as tourist and export markets. 
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Country National? Year passed Comments 
Medical 
Colombia Yes 2015 The decree signed in December 2015 permits medical cannabis 
under national drug law. The new decree may be modified or 
superseded by a bill that has been submitted to Congress, but it 
has paved the way for state-licensed commercial production, 
although it is unclear how much cannabis production will be 
permitted. 
Australia Yes 2016 A law was passed at the Commonwealth level to create a 
regulatory framework for commercial cannabis production for 
medical purposes. (A Tasmanian law passed in 2015 pertained only 
to providing cannabis for research purposes in New South Wales.) 
Germany Yes 2017 Before the law passed, there were about 1 000 individuals who 
had received special permission to use cannabis for medicinal 
purposes; the cannabis was imported. The new law expands access 
and allows domestic production. 
Non-medical 
United States No 2012 (a) Eight states have passed laws to allow for-profit companies to 
produce and sell cannabis (Alaska, California, Colorado, Maine, 
Massachusetts, Nevada, Oregon and Washington) to anyone aged 
21 or older; Washington DC allows only home production and 
sharing. Production, distribution, and possession remain illegal 
under federal law. 
Uruguay Yes 2013 Residents aged 18 or older must register with the government to 
either grow at home, join a collective or purchase cannabis from 
pharmacies.  
Sources: Reproduced in updated form from Kilmer and Pacula (2017); The Local (2017). 
(a) In countries where subnational jurisdictions have passed laws, the date represents when the first such law 
passed.  
 
There are important differences between the United States and Europe when it comes to medical 
cannabis, and medicine in general. Indeed, while the United States is notorious for having a 
prescription medicine system that relies on heavy promotion to physicians and patients, direct-to-
consumer advertising of these products is forbidden in Europe. Medical officials in the United States 
cannot legally prescribe cannabis because of the federal prohibition, but they can make 
‘recommendations’ that patients can take to ‘dispensaries’ that sell only cannabis products (in some 
states, patients are also permitted to grow cannabis at home (Pacula et al., 2002; Pacula et al., 
2015). Depending on the state, it can be very easy to obtain a recommendation and there may be 
advertising for medical cannabis (e.g. D’Amico et al., 2015). The situation is very different in the 
Netherlands and the Czech Republic, where medical cannabis is prescribed by doctors, obtained at a 
regular pharmacy and not promoted. 
Table 1 (continued) 
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De jure versus de facto changes 
A final distinction in relation to cannabis reforms is whether or not they are based on official changes 
to cannabis laws. Until 2012, none of the reforms related to supplying non-medical cannabis were 
the result of national legal changes. For example, cannabis remains technically illegal in the 
Netherlands, but the Dutch have a formal policy against enforcing the law against small transactions 
and coffee shops that comply with regulations.  
Spain’s CSCs inhabit a grey area, since Spanish law criminalises only sale (Barriuso, 2011). Some of 
the Spanish clubs supply only members while others appear to be less restrictive. This has been the 
subject of a series of court cases, with Hughes et al. (2017) noting: 
In Spain, three Supreme Court decisions of 2015 declared organized cultivation by clubs 
open to new members as a trafficking crime. However, a legal change in the same year 
defined the offence of personal cultivation, similar to that of use, to be committed only if 
the growing was in public view, perhaps implying that personal cultivation and use in private 
is now not an offence of any kind, comparable to Washington DC. 
While some of these CSCs have been shut down, hundreds of them are tolerated by local law 
enforcement agencies (PRI, 2016). These types of clubs are operating in Belgium and other countries 
but are not explicitly allowed (Decorte, 2015; Belackova et al., 2016; EMCDDA, 2016). 
The bottom panel of Table 1 shows the two countries where laws have been changed to allow 
cannabis to be produced and sold for non-medical purposes. Uruguay became the first country in 
the world to remove the prohibition on cannabis. It allows residents aged 18 or over to access it 
through one of three mechanisms: (i) grow it at home; (ii) obtain it from a CSC; or (iii) purchase it 
from a pharmacy. To obtain legal cannabis, residents must register with a government agency and 
select only one approach. The pharmacy option is still being implemented (Cerdá and Kilmer, 2017) 
and users will be allowed to purchase up to 40 g per month (Queirolo et al., 2016). The government 
will control the price and potency of what is sold in pharmacies and advertising will not be allowed 
(Walsh and Ramsey, 2015). 
Eight states in the United States have now passed ballot initiatives to remove cannabis prohibition 
and allow profit-maximising firms to produce and sell cannabis products to anyone aged 21 or 
older (5). Colorado and Washington State both had very lax medical programmes (i.e. it was easy to 
obtain a recommendation and find a dispensary) before their non-medical laws were passed in 2012. 
Alaska and Oregon followed in 2014, and in 2016 voters in California, Maine, Massachusetts and 
Nevada also passed initiatives to allow for-profit companies to supply cannabis. While all of these 
efforts remain illegal under federal law, the Obama administration decided to tolerate these 
violations as long as states had ‘implemented strong and effective regulatory and enforcement 
systems’ (Cole, 2013). It is unclear what the Trump administration will do about cannabis; it has a 
number of options (Kilmer, 2017a). 
                                                            
(5) There are a number of reasons voters claimed to support these initiatives (e.g. to shrink the illicit market, to 
generate tax revenue for the government, to reduce criminal justice expenditures and to eliminate 
racial/ethnic disparities in cannabis arrest rates). 
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The cannabis debate in the United States has focused largely on a false dichotomy: continue to 
prohibit supply or create a for-profit industry. Jurisdictions considering cannabis supply reform can 
choose from a number of ‘middle-ground’ options such as home production, CSCs, a state monopoly 
and a non-profit approach (Figure 1) (Caulkins et al., 2015; Wilkins, 2016). Indeed, what is often 
overlooked in the United States and elsewhere is that, in 2014, the voters of Washington DC 
removed the prohibition on cannabis but did not permit commercial sales. Adults are allowed to 
grow and give away cannabis; it cannot be sold. 
 
 
Figure 1. Alternatives to status quo cannabis supply prohibition 
 
 
Source: Adapted from Caulkins et al., 2015. 
It is likely that the next country to legalise cannabis for non-medical purposes will also be in the 
Western Hemisphere. In April 2017, a bill to legalise cannabis production and possession (referred to 
as C-45) was introduced into the House of Commons of Canada (6). Among other actions, the bill 
would remove prohibition and allow the federal government to regulate for-profit producers. 
Decisions about retail supply would be left up to the provinces and territories, and the government 
of Ontario recently reported that it would choose a middle-ground option and limit cannabis sales to 
government-run stores (Skerritt et al., 2017 ).  
                                                            
(6) http://www.parl.ca/DocumentViewer/en/42-1/bill/C-45/first-reading. Those seeking a summary of the bill 
and the task force’s report should visit http://www.justice.gc.ca/eng/cj-jp/marijuana/c45/c45.pdf. 
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What is the evidence about the impact of these reforms? 
Most of the evidence on cannabis supply reforms has focused on the coffee shop policy in the 
Netherlands and medical cannabis in the United States. This section briefly highlights the relevant 
literature in these areas, as well as the emerging data from non-medical legalisation in Colorado and 
Washington. 
Coffee shop policy in the Netherlands 
Cannabis remains technically illegal in the Netherlands, but the Dutch make enforcing the law 
against small-scale cannabis transactions the lowest priority. For nearly 40 years, the Netherlands 
has tolerated ‘coffee shops’ — where cannabis can be consumed on the premises and/or purchased 
for off-site consumption — as long as the shops are compliant with a number of specified criteria (7). 
MacCoun and Reuter (2001a, 2001b) found that Dutch prevalence rates uniquely increased in the 
1984-1992 period, leading them to hypothesise that ‘the dramatic mid-1980s escalation in Dutch 
cannabis use is the consequence of the gradual progression from a passive depenalisation regime to 
the broader de facto legalisation which allowed for greater access and increasing levels of 
promotion’, through the growth in coffee shops; however, this interpretation has been the subject 
of debate and additional analysis (de Zwart and van Laar, 2001; MacCoun and Reuter, 2001c; 
MacCoun, 2011). More recent work by Palali and van Ours (2015) finds that those growing up within 
20 km of a coffee shop have a lower age of cannabis initiation. 
 
Researchers have exploited recent changes in Dutch coffee shop policy to learn more about the 
consequences of restricting cannabis availability. In 2011, the city of Maastricht temporarily 
restricted access to its coffee shops to residents of Belgium, Germany and the Netherlands. Using 
administrative course grade data from students enrolled at Maastricht University before and after 
the policy change, Marie and Zolitz (2017) found that the academic performance of students who 
were no longer legally permitted to buy cannabis increased substantially, especially for courses that 
require more numerical/mathematical skills. To the extent that it would still be possible for excluded 
students to obtain cannabis from coffee shop customers or the street market, the authors suggest 
their findings could underestimate the true effect. 
 
In 2012, national cannabis policy was tightened in the Netherlands to limit coffee shops to members, 
who had to be Dutch citizens. As noted by van Ooyen-Houben et al. (2016), there were three goals 
for the new policy: (i) to reduce drug tourism from other countries, (ii) to minimise nuisance 
associated with the coffee shops and (iii) to make the coffee shops smaller and easier to control. 
There was tremendous variation in the implementation of these regulations, with many jurisdictions 
choosing not to implement them. There were soon national changes, with the membership criterion 
being lifted in 2012 and the residence criterion amended in 2013, making implementation subject to 
local decision-makers. However, van Ooyen-Houben et al. (2016) found that in places that 
implemented the new criteria there was a swift decline in drug tourism and a reduction in coffee 
shop purchases by locals, as many Dutch users did not want to register to become members. The 
authors report that driving the trade outside of coffee shops led to an increase in illicit transactions 
                                                            
(7) For more information on the criteria, see https://www.government.nl/topics/drugs/toleration-policy-
regarding-soft-drugs-and-coffee-shops. 
 10 
and nuisance complaints about street sales. After the membership criterion was removed, many 
local consumers returned to the coffee shops, but others still made purchases on the street. The 
authors concluded, ‘The quick and robust shifts in the users’ market in reaction to the policy changes 
illustrate the power of policy, but also the limitations caused by the dynamic and resilient nature of 
the Dutch cannabis supply market.’ 
Medical cannabis in the United States 
There has been some debate in the United States about whether or not state-level medical laws 
were a ‘Trojan horse’ intended to open the door for non-medical reforms (see Kilmer and MacCoun, 
2017, for a discussion), but that does not negate the fact that hundreds of thousands of patients in 
the United States have benefited from having access to medical cannabis. 
Given that a number of US states have lax medical cannabis systems, there are concerns that these 
laws will increase the use of cannabis for non-medical purposes. Based on a framework developed 
by MacCoun (1993), Kilmer and MacCoun (2017) describe five mechanisms by which medical laws 
may increase cannabis consumption: decreasing legal risk, decreasing stigma, increasing availability, 
increasing promotion and decreasing price. They also note that there could be a ‘forbidden fruit’ 
effect whereby those who use cannabis because it is illegal and perceived as dangerous may find it 
less attractive once it is considered a medicine. 
There is a large and growing literature examining state-level variation in these laws in the United 
States. Many of the early studies used a binary measure to classify states as having a medical law or 
not, thus ignoring the tremendous heterogeneity in these policies (Pacula et al., 2015). The more 
advanced studies try to account for this variation by examining the specifics of these laws (e.g., are 
dispensaries allowed? Home cultivation?) and the size of the programmes. A recent review of this 
literature by Pacula and Smart (2017) concludes: 
While findings tend to be mixed when the literature is looked at as a whole, some consistent 
themes seem to emerge when the literature is instead considered with an eye toward 
differences between policies and populations. For example, studies that examine medical 
marijuana markets in a manner that is attentive to the development of these markets, either 
through measures of the presence of active dispensaries or the size of the market, seem to 
consistently show a positive correlation of these policies with use among high-risk users 
(arrestees, those in need of treatment, and polysubstance users). Similarly, many studies 
have shown a positive association with adult use of marijuana while most have found no 
association with youth prevalence or frequency of use in general school populations. 
The literature about medical cannabis laws and alcohol consumption is inconclusive (Kilmer and 
MacCoun, 2017), but, given the public health importance of this issue, it will continue to be the 
subject of research. There is also a growing literature about how these medical cannabis laws may 
affect the use of opioids (8). One hypothesis is that some patients prefer to use cannabis rather than 
opioids for treatment and will reduce opioid consumption if cannabis is available. Another 
hypothesis is that diversion of medical cannabis to the non-medical market may increase availability, 
                                                            
(8) There is also an emerging literature about the effects of medical cannabis laws on traffic safety (e.g. 
Anderson et al., 2013; Kim et al., 2016; Santaella-Tenorio et al., 2016). 
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which could make cannabis more attractive than opioids to those seeking intoxication. Both could be 
true at the same time, and there may be other explanations. Kilmer and MacCoun (2017) summarise 
the quasi-experimental literature on the association between medical cannabis laws and opioid 
outcomes, finding: 
[M]ost peer-reviewed studies suggest increased availability of medical marijuana is 
negatively associated with opioid-related outcomes (9) such as opioid overdose deaths at the 
state level (Bachhuber et al. 2014), prescriptions for painkillers among Medicare Part D 
enrollees (Bradford & Bradford 2016), prescriptions for pain killers among Medicaid 
enrollees (Bradford & Bradford 2017), and opioid positivity among 21- to 40-year-old fatally 
injured drivers (Kim et al. 2016). That said, the peer-reviewed studies have been criticized 
for overplaying the causal mechanisms at play, which is very difficult to determine when 
working with aggregate-level data (Finney et al. 2015; Caputi & Humphreys 2016).   
There are also papers undergoing peer review that use stronger methodologies and yield consistent 
findings about the association between medical marijuana availability and opioid overdoses (Powell 
et al., 2015; Smart, 2015). Considering that the United States is in the middle of an opioid crisis, it is 
unclear whether or not these associations would hold elsewhere. 
Non-medical cannabis in the United States 
The causal mechanisms by which increasing the availability of medical cannabis could influence 
overall cannabis use also apply to laws that legalise cannabis for non-medical purposes (Caulkins et 
al., 2015). Of course, much will depend on the type of regulation that is implemented. The effects of 
simply allowing small-scale home cultivation are likely to be much smaller than those of licensing 
profit-maximising firms to advertise and produce/sell as much as they want.  
It is too early to conduct most of the rigorous analyses needed to evaluate the overall effects of 
commercial legalisation in the United States (Caulkins et al., 2016; Hall and Lynskey, 2016; Subritzky 
et al., 2016; Kilmer and MacCoun, 2017) (10). While Colorado and Washington legalised cannabis in 
2012, retail stores did not open in these states until January 2014 and July 2014 respectively (and 
Washington furthermore had a slow roll-out, since unlike Colorado it did not allow medical 
dispensaries to use their existing inventories). That said, we do know that overall possession arrests 
have decreased (although an increase in the cannabis arrest rate for Hispanic and African-American 
youth in Colorado is troubling) (Colorado Department of Public Safety, 201611), tax revenues are 
coming in and concentrates have created challenges for regulators. Cannabis-related pediatric 
emergency room visits have increased by a large percentage in Colorado, but this is based on a very 
                                                            
(9) They noted, ‘Wen et al.’s (2015) paper is the exception; they did not find a statistically significant 
association between medical marijuana laws and prescription pain killer misuse.’ 
(10) There is a substantial amount of sub-state variation in the implementation of legalisation in states that 
have passed these initiatives (e.g. Dilley et al. (2017) report that ‘As of June 30, 2016, 30 % of the state 
population lived in places that had temporarily or permanently banned retail sale’.). In the short term it is 
expected that more will be learned from studies examining within-state variation than from those examining 
across-state variation. 
(11) This finding about Hispanic and African-American youth in Colorado is based on an analysis using data 
through 2014.  I am not aware of more recent analyses examining the cannabis arrest rates for these groups.  
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low base rate (Wang et al., 2016), and it is hard to determine how much of the increase is 
attributable to parents feeling less stigma about reporting cannabis as the reason for the visit (12). 
As for cannabis use, the US federal government is able to produce state-level estimates of past-year 
and past-month cannabis prevalence by combining two years of annual general population survey 
data from the National Survey on Drug Use and Health (SAMHSA, 2016). Figure 2 displays the self-
reported past-month cannabis prevalence rates for the entire US as well as Colorado and 
Washington from 2002/2003 to 2014/2015. Nationally, past-month cannabis prevalence for those 
aged 12 or older increased by 4.8 %, from 7.96 % in 2013/2014 to 8.34 % in 2014/2015 (p = 0.001). 
Interestingly, Colorado and Washington display different trends over this period. While Colorado 
saw an 11 % increase over this period (from 14.93 % to 16.57 %; p = 0.063), Washington saw a 12 % 
decrease (from 12.79 % to 11.22 %; p = 0.019). 
Figure 2. 
Self-reported past-month cannabis prevalence for those aged 12 and older in Colorado, 
Washington, and the US, 2002/2003 – 2014/2015 
 
Source: SAMHSA, annual  
Even if both states had seen an increase over this period, it would be incorrect to use these simple 
trend data alone to make strong inferences about legalisation. First, much depends on the year one 
uses for the base estimate. For example, while the recreational stores opened in Colorado in January 
2014, all of the initial stores were pre-existing medical dispensaries. Some have argued that real 
commercialisation and expansion in Colorado started around 2009, not 2014 (e.g. Ghosh et al., 2015; 
Rocky Mountain High Intensity Drug Trafficking Area, 2016). Second, there are other factors that 
influence prevalence aside from cannabis policy (see, for example, Jacobson, 2004); rigorous 
                                                            
(12) There is also a lot of discussion about the effect of non-medical legalisation on traffic safety; however, the 
author is aware of only one peer-reviewed study that examines the effect of these laws on overall traffic 
crashes or fatalities (Aydelotte et al., 2017). Rigorous analyses will look beyond drivers in crashes who test 
positive for THC (Caulkins et al., 2016). For information about medical cannabis laws and traffic safety, see 
note 8. 
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analyses will attempt to control for them. Third, some of the increase in self-reported use in 
legalisation states may be attributable to respondents being more honest about their cannabis use 
(Kilmer and Pacula, 2017). Fourth, from a health perspective, we care more about quantity 
consumed than whether or not someone has used cannabis in the past month; however, the survey 
does not ask about amount consumed (and the state-level estimates do not include information 
about the number of days used in the past month). Fifth, if the goal is to evaluate the public health 
and public safety consequences of legalisation, analysts must look at how legalisation influences the 
use of alcohol, tobacco, opioids and other substances (Caulkins et al., 2016). 
The first peer-reviewed, multi-state, individual-level analysis exploring the association between 
cannabis legalisation and youth prevalence was published by JAMA Pediatrics in February 2017 
(Cerdá et al., 2017). Using the Monitoring the Future (MTF) school survey data and controlling for a 
number of individual-, school- and state-level factors in a differences-in-differences design, the 
authors found no effect of passing a law legalising cannabis for 8th, 10th, and 12th grade students in 
Colorado (the study examined changes from when the law became effective in January 2013, not 
from when stores opened). In Washington, they similarly found no significant association between 
passing the legalisation and marijuana use among 12th grade students, but they did find small 
statistically significant increases in past-month cannabis prevalence for 8th and 10th grade students 
in Washington (relative to students in states that had not legalised). These were the same age 
groups in Washington that showed a significant decline in perceived harmfulness of cannabis.  
The MTF survey does not produce state-representative samples and roughly 5 500 Washington 
students were included in the analysis (fewer than 1 000 students per year, 2010-2015, from a total 
of 30 schools). The authors of the study noted, ‘A greater number of schools would have been 
advantageous, and the sample design may lead to discrepancies between MTF results and those 
found in other large-scale surveillance efforts.’  Washington State conducts a biennial Healthy Youth 
Survey (HYS), which includes the vast majority of 6th, 8th, 10th and 12th grade students (in 2016, 
the sample size exceeded 230 000 students, from more than1 000 schools). From this large sample, a 
representative sample is created and the results do not suggest that past-month cannabis 
prevalence for Washington’s 8th or 10th graders increased after the legalisation change; if anything, 
the raw data suggest the rate decreased (HYS, various years). Advanced multivariate analyses with 
HYS data are currently being conducted, but this highlights how inferences about legalisation may 
depend on the data sources being considered. 
What are the implications for drug policy and practice in Europe?  
When considering the implications of these policy changes and of this emerging evidence, it is 
important to step back and consider the goals of these cannabis reforms. In the Netherlands, one of 
the main justifications for the coffee shop regime was to reduce youth contact with dealers who 
might be selling more dangerous drugs. In the United States, many arguments were offered by 
legalisation proponents, such as reducing the size of the illicit market, generating significant tax 
revenues, reducing criminal justice interactions and protecting public health with testing and 
labelling. There were other health claims, such as a reduction in youth consumption, because ‘drug 
dealers don’t check identification’, and a reduction in alcohol use, but the evidence for these claims 
remains to be seen. In Uruguay, legalisation was not motivated by tax revenues; the main focus was 
on reducing the violent crime associated with Paraguayan drug distributors. In Canada, there seems 
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to be a lot of emphasis on the public health implications, with the Task Force on Cannabis 
Legalization and Regulation (2016) reporting, ‘Our recommendations reflect a public health 
approach to reduce harm and promote health.’ 
The goals of the cannabis reform will shape decisions not only about how cannabis is supplied 
(Figure 1), but also about how it is regulated; however, no one knows the best way to legalise and 
regulate cannabis supply. While some insights can be drawn from the extensive research on alcohol 
and tobacco regulation (Pacula et al., 2014; Barry and Glantz, 2016), cannabis is a unique substance 
that can be consumed in an increasing number of forms. Table 2 highlights a number of regulations 
that could be applied to cannabis, focusing on four major areas: product, seller/server and sales, 
marketing, and possession or use (Caulkins et al., 2015). 
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Table 2. Examples of regulations that could be applied to cannabis 
(examples are not necessarily endorsements) 
Area of regulation  Precedent pertaining to currently legal 
products 
Example of application to 
marijuana 
Product   
Types of products 
that are permitted  
At various times, jurisdictions have banned 
absinthe and Everclear, even when allowing 
most types of alcohol.  
Restrict legalization to just 
usable marijuana plant 
materials (herbal cannabis).  
Additives or 
products attractive 
to children  
Flavourings (except menthol) are banned from 
cigarettes.  
Ban fruit flavours and 
marijuana-infused candies.  
Potency or 
strength  
Many states restrict sale of products with more 
than 10% ethanol from being sold in grocery 
stores.  
Create а ТНС ceiling or а CBD 
floor.  
Product labelling  Australia adopted plain packaging for all tobacco 
products in 2012; similar efforts are being 
pursued in other countries.  
Require unbranded packaging, 
devoid of logos or any form of 
commercial design.  
Packaging  Child-resistant packaging is standard on а 
variety of household items, including 
prescription and over-the-counter medications, 
vitamins, pesticides, and household chemicals. 
Require marijuana products to 
be sold in resealable, opaque, 
child-resistant containers. 
Seller or server and sales 
Inventory-control 
system  
Both Washington and Colorado are 
implementing inventory-control systems for 
recreational marijuana.  
Require all licensees throughout 
the supply chain to participate 
in inventory-control system.  
Age of sellers and 
servers  
Many states impose а minimum age restriction 
of 21 for serving alcohol.  
Require that anyone selling or 
handling marijuana in stores be 
at least 21 years old.  
Vendor and server 
training and 
responsibilities  
Many states require training for those who 
serve alcohol to (1) ensure they check the 
patron's age, (2) identify people at risk of 
excess, and (3) understand their legal 
responsibilities and risks as servers. 
Require specific training course 
that includes how to advise 
consumers on potency and 
related risks.  
Sold in certain 
types of outlets 
only  
Many liquor-control states limit sale for 
off-premises consumption to specialized 
alcohol-only stores.  
Require that marijuana be sold 
only in marijuana-only stores.  
Outlet density and 
location  
Washington restricts the total number of legal 
marijuana outlets and requires that licenses  
be distributed across the state according to 
consumption data. 
Limit outlet density to ensure 
that there is no over-availability 
in any area.  
Vending machines  The United States restricts tobacco-vending 
machines to establishments with over-18 age 
restrictions.  
Prohibit sales of marijuana 
products in vending machines.  
Days of sale and 
hours of operation  
Most states limit the times when alcohol can be 
sold. Several states ban sale of alcohol for off-
premises consumption on Sundays.  
Restrict sales of marijuana to 
the same outlet hours as alcohol 
sales.  
Happy hours and 
bulk discounts  
Many U.S. states ban happy-hour pricing for 
alcohol sales.  
Prohibit happy-hour pricing and 
discounts with bulk purchases.  
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Area of regulation  Precedent pertaining to currently legal 
products 
Example of application to 
marijuana 
Quantity and 
promotional 
discounting, free 
samples  
ln response to grocery stores using alcohol as а 
loss leader to get people into the stores, the UK 
banned promotions that sold alcohol below 
cost.  
Prohibit coupons, discounts, and 
giveaways (e.g., free marijuana 
with purchases of other goods).  
Sales quotas and 
limits  
Dutch coffee shops limit marijuana sales to no 
more than 5 g per purchase, and Uruguay limits 
pharmacy purchases to 40 g per month (no 
more than 10 g per week).  
limit the amount of marijuana 
that can be purchased with in а 
day or month (e.g., tied to 
driver's license).  
Non-resident 
access  
ln Colorado, а non-resident can purchase only 
up to 0.25 oz. of herbal marijuana at а time; а 
resident can purchase up to 1 oz.  
Restrict sales to residents only.  
On-premise 
consumption  
Various jurisdictions ban consumption in 
marijuana dispensaries; Washington State bans 
marijuana use in any establishment with а liquor 
license.  
Allow the marijuana equivalent 
of liquor stores but not bars; 
ban consumption of marijuana 
at establishments that serve 
alcohol.  
Product placement  As of 2010, FDA has restricted the sale of 
tobacco products in vending machines and self-
service displays; they can be sold only behind 
the counter.  
Ban self-service displays and so 
require а store assistant to 
access.  
Minimum pricing  Many states have minimum pricing laws for 
cigarettes.  
Require that 1 mg of ТНС be 
sold for no less than а certain 
price.  
Marketing   
Physical location 
and size of 
advertising  
Washington bans advertising within 1 000 ft. of 
schools and playgrounds; in the Netherlands, 
only establishments that refrain from 
advertising are exempted from marijuana law 
enforcement.  
Prohibit off-premise advertising.  
Electronic 
advertising  
Finland bans alcohol-branded social media 
communication.  
Make refraining from 
sponsoring games and other 
online contests а condition for 
licensure.  
Product placement 
and sponsorship  
FDA bans the tobacco industry from sponsoring 
sporting and entertainment events.  
Prohibit marijuana firms from 
sponsoring sporting and 
entertainment events and any 
event at а school.  
Ads targeting 
youth 
Both the tobacco companies and the beer 
industry have been challenged for the use of 
youth-oriented marketing materials. Joe Camel 
was effectively removed because of court 
challenges. 
 
 
 
 
 
 
Prohibit use of cartoon figures, 
animals, and other marketing 
images geared toward youth.  
Table 2 (continued) 
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Area of regulation  Precedent pertaining to currently legal 
products 
Example of application to 
marijuana 
Possession or use   
Age of possession, 
use, and purchase 
Most states allow civil and sometimes criminal 
penalties for minors caught possessing, using, or 
purchasing cigarettes or alcohol, although 
tobacco PUP laws are weakly enforced. 
Restrict possession, use, and 
purchasing by people under  
21 years of age. 
   
Method of 
consumption 
Many states have strict rules pertaining to 
purchasing а keg of beer so as to reduce the 
chances that keg parties are possible for youth 
and young adults. 
Prohibit forms of cannabis 
suitable for dabbing. 
Use in public Many states have open-container laws 
effectively banning alcohol use in public and 
implement strict clean-indoor-air laws limiting 
where cigarettes may be smoked. 
Prohibit the use in all places 
where tobacco is also prohibited 
or in all public spaces more 
generally. 
Use before or 
while driving  
Most states ban open alcohol containers in а 
car; all limit ВАС as measured by а breathalyser. 
Colorado and Washington limit active ТНС per 
unit of blood for drivers, but there is not а 
practical roadside test for that, akin to 
breathalyser readings being assumed 
proportional to ВАС. 
Limit active ТНС per unit of 
blood for drivers. 
Possession of 
diverted (non-tax-
paid) product  
Many states ban possession of non-tax-paid 
alcohol. 
Impose criminal penalties on 
possession of marijuana that 
does not bear а Vermont tax 
stamp.  
Providing access to 
minors  
Many states have social-host policies that hold 
property owners responsible for underage 
drinking occurring on their property. Both state-
imposed liability and private-party civil liability 
apply. 
Impose civil penalties on those 
who provide access to 
marijuana to minors, and 
extend social-host policies to 
marijuana.  
Prevention  Many states, including California, increased the 
sales tax on cigarettes with а specified share 
going to an anti-tobacco public-health 
campaign. 
Require that а substantial 
proportion of revenue 
generated by marijuana sales go 
to prevention campaigns 
designed or run by the state 
public-health agency.  
NB: The fact that an example is listed is not necessarily an endorsement. FDA = U.S. Food and Drug 
Administration. PUP = purchase, use, and possession. ВАС= blood-alcohol concentration. 
Source: Reproduced from Caulkins et al., 2015.  
 
Among the plethora of decisions confronting jurisdictions considering alternatives to cannabis 
prohibition is whether or not to limit the types and potency of products that are to be made legally 
available So far, none of the US states that have legalised cannabis for non-medical purposes has 
limited the potency of cannabis flowers or extracts that can be purchased; there have been some 
limits imposed on edibles. This is leading to a proliferation of high-potency cannabis products in 
legalisation states. For example, the majority of flower sold in Washington is labelled as being 
Table 2 (continued) 
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greater than 20 % THC, and some of the concentrates (e.g. waxes, shatter) can exceed 75 % THC 
(Smart et al., 2017). We know very little about the health consequences of the higher-potency 
products and whether or not users are titrating their THC consumption (Kilmer, 2017b) (13). One 
option for risk-averse jurisdictions is to initially limit potency and product types for the non-medical 
market until more is learned about the health consequences. 
Another area where EU Member States can learn from recent innovations is with respect to taxation. 
There are a variety of ways to tax cannabis and each comes with a number of potential trade-offs 
(Caulkins et al., 2015; Oglesby, 2017). For example, most of the legalisation states in the United 
States tax cannabis as a function of price, which is very easy to implement. For jurisdictions 
concerned about collecting revenues, however, a drawback to this approach is that, as the price of 
cannabis drops, so will the revenue. In addition, and if jurisdictions do not explicitly prohibit 
bundling, profit seekers will find a way to beat the tax (e.g. ‘I’ll sell you this pipe for 50 euros and 
give you the cannabis for free’). Alternatively, the state of Alaska is taxing cannabis as a function of 
weight, which is easy to implement but raises concerns that it creates incentives to sell more potent 
products. Another approach is to tax cannabis as a function of potency (MacCoun, 2010; Caulkins et 
al., 2013, 2015), which was recommended by Canada’s cannabis task force. Taxing as a function of 
THC (or the THC to CBD ratio) would give governments the power to nudge users to lower potency 
products, but it would be dependent on having a reliable testing and labelling system. There is much 
to learn about all of these tax regimes — including their unintended consequences — and the 
European Union (EU) can learn from the mistakes of and challenges faced by early adopters. 
Finally, some EU Member States may be interested to see what these changes mean for the 
international drug control treaties. How do countries that legalise cannabis address — or not 
address — their obligations to the treaties? Will it create a precedent that others will follow? The 
International Narcotics Control Board argues that Uruguay’s cannabis law is a breach of ‘the 
universally agreed and internationally endorsed legal provisions of the treaty’. In response, it was 
reported that President Mujica’s government argued ‘that the new law is entirely consistent with 
the original spirit of the UN drug treaties to promote the “health and welfare of mankind” and is 
aligned with Uruguay’s fundamental human rights obligations’ (Hetzer and Walsh, 2014). 
There is a heated debate about whether or not the United States is in violation, since the federal 
government, which signed the treaty, still prohibits cannabis (see, for example, Humphreys, 2013; 
TNI, 2015). This debate will continue, but federal toleration would seem to make it difficult — or at 
least quite hypocritical (Walsh and Ramsey, 2015) — for the United States to voice disapproval 
about other countries violating the conventions, at least with respect to cannabis. Indeed, the US 
government has not made a public statement about the Uruguayan law. If Canada does legalise 
cannabis, it will not only be interesting to see how it addresses its obligations to the conventions, it 
will also be revealing how the United States and other countries react to the Canadian approach. 
Since Canada is a much larger country than Uruguay and a member of the G7, its actions and the 
responses they receive — or do not receive — could have ripple effects outside North America. 
                                                            
(13) Future potency debates are likely to focus on THC to CBD ratios. For a useful review, see Englund et al. 
(2017). 
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Conclusion 
As more jurisdictions contemplate and pass laws to legalise cannabis for medical and non-medical 
purposes, the discussions about cannabis policy will likely become more intense in the EU. Member 
States can learn from these experiences and decide if they want to maintain their current cannabis 
supply policies or try something else. Those considering alternatives should remember that change 
need not be permanent; however, if profit-maximizing firms are allowed to produce and sell 
cannabis, they will have strong incentives to fight against regulations and policy changes that will 
negatively affect their bottom lines. 
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